Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Allegations Against 3M Corporation of Possible "Negligence and Recklessness" by The Porton Group, the Equity Partner of the British Ministry of Defence, for "Botched" U.S. Testing of Lifesaving Device to Detect the MRSA "Superbug"/Staph Infection

- At an International Press Conference in Minneapolis, U.S. Attorneys for Porton Petition FDA to Investigate 3M for Allegedly Ignoring FDA Advice, Failing to Disclose Secret Internal Technical Committee Report on Testing Errors, and for Possible Financial Conflicts of Interest


News provided by

The Porton Group

11 May, 2011, 17:47 GMT

Share this article

Share toX

Share this article

Share toX

MINNEAPOLIS, May 11, 2011 /PRNewswire/ -- The famous U.S. 3M Corporation today was alleged by the private equity partner of the British Ministry of Defence, the Porton Group, to have exhibited "negligence and possible recklessness putting lives at risk" due to 3M's "botched" 2007 clinical trials of a medical device called "BacLite," which can detect within five hours the presence of the potentially deadly MRSA/staph "superbug." The trials were conducted after notification of the U.S. Food and Drug Administration (FDA) and after seeking FDA advice, which 3M proceeded to ignore, according to Porton and public legal papers.

MRSAs have killed more people annually than AIDS. The only alternatives to BacLite's inexpensive, five-hour or less detection system available today are either far more expensive, DNA/molecular detection systems, or growth solutions, which take 1-2 days to detect the presence or absence of MRSAs. BacLite was invented by researchers in the British Ministry of Defence using photo-fluorescent technology based on the firefly and originally seeking to identify biological weapons of mass destruction, such as Anthrax.

At a press conference today in Minneapolis, next door to "twin city" St. Paul, Minnesota, home of 3M's international headquarters, attorneys for Porton, Lanny J. Davis of Washington, D.C. and Robert Hopper of Minneapolis, cited a secret report by an 11-member internal 3M technical committee that confirmed 3M testers had made fundamental errors that led to unacceptable 50% reliability results. These results were in contrast to the 95%+ results achieved in 2006 in British-run trials when the Porton and the U.K. Ministry of Defence still owned BacLite, i.e., meaning European Union (EU) regulators allowed the sale of BacLite to British hospitals to begin in 2006 based on verifiable test trial results.

The secret 3M report cited many errors by 3M testers such as refrigerating the "comparator" solution at temperatures colder than test protocols permitted, thus artificially impeding the growth of MRSAs; and the use of a different comparator solution than had been used in the successful European trials, despite FDA's allegedly express approval of using the same comparator as was used in Europe.

Background of 3M Purchase of BacLite

In approximately late 2006, 3M's chairman and CEO, George Buckley, through an intermediary, sought to purchase rights to the British Ministry of Defence-invented "BacLite," a rapid, inexpensive, MRSA-detection device approved for sale in Europe in 2006. A purchase and sale contract was signed in February 2007 between 3M and the combined company, Acolyte, comprising the British- Ministry of Defence-wholly-owned subsidiary, Ploughshare, and a group of equity investors called The Porton Group. 3M had approached Acolyte and argued that it was in the best position to maximize global sales of BacLite given its own health products division expertise and its global experience. 3M did due diligence on the efficacy of BacLite, including data from the U.K. clinical trials, and after its purchase, touted those data from the U.K. trials and the reliability of BacLite on its own website and its marketing procures. (See Exhibit A, H).

In the purchase and sale contract signed in February 2007, 3M promised to "actively" market BacLite and to obtain regulatory approvals "diligently" in the U.S., Canada, and Australia.

At an international telephonic press conference held today in Minneapolis, Minnesota, a short distance from 3M's corporate headquarters in St. Paul, Minnesota, Porton's U.S. attorneys, Lanny J. Davis of Washington, D.C. and Robert Hopper of Minneapolis, Minnesota, announced they were filing today a "citizens' petition" and letter with the FDA seeking an investigation of 3M and a public hearing under applicable FDA regulations.

Grounds for FDA Investigation and Hearing

The attorneys cited at least three grounds for FDA under applicable regulations to conduct such an investigation and public hearing in claiming there was evidence that 3M had possibly misled the FDA when it:

- failed to disclose to FDA the contents of the secret technical report on the multiple errors leading to failure of the U.S. trials;

- failed to explain why another round of tests were not conducted consistent with its own technical committee's and FDA's advice; and

- failed to disclose possible financial conflicts of interest that might explain such 3M decisions as:

- not re-doing the clinical trials in November 2007 to correct the errors pointed out by its own internal technical committee in their secret report;

- withdrawing BacLite entirely from the European market at the end of 2008, one year from the term of the purchase and sale contract;

- at the end of 2008, removing BacLite system equipment from some U.K. hospitals, despite being told by some hospital personnel that, according to one physician, BacLite was "easy to use" and "very reliable" and "could save lives;" and

- in May or June 2009, with more than six months to go in its purchase and sale contract, appearing to announce an effort to sell its own more expensive competitor to BacLite called "FastMan," which used molecular technology to detect MRSAs but had not met reliability standards (and still hasn't). (Just recently, on its Internet cite, 3M's medical products division is promoting apparently another similar product, "Simplexa.")

Statements by Equity Investors and British Government Co-Owners of BacLite

Harvey Boulter, the CEO of the Porton Group, issued a public statement saying

"We trusted 3M when they urged us to sell after promising in writing they would 'actively market' this product globally and, specifically, would 'diligently' seek to obtain regulatory approvals in the U.S., Canada, and Australia" through the end of 2009," Mr. Boulter continued. "But we believe they broke that promise, and we believe it is possible that, as a result, hospital patients in Europe, the U.S., and all over the world could have been unnecessarily exposed to MRSAs."

"We will not rest," he stated, "until 3M is held accountable for walking away from its obligations."

The CEO of the company wholly owned by the British Ministry of Defence, Mr. Pete Hotten, also issued a written statement, unusual for a representative of the British government.

Mr. Hotten stated: "We are disappointed that 3M Corporation failed to get an excellent diagnostic technology [to detect MRSAs in incoming hospital patients] into the market, though what 3M's own [technical committee] officials describe as avoidable mistakes. [We] believe 3M's decision not to correct their mistakes and to reapply for FDA approval is contrary to its obligation to its partners."

Legal Authorities for Porton Petition and Request for FDA Investigation/Hearing

The two attorneys who signed the public petition to the FDA and the letter, Messrs. Davis and Hopper, cited several FDA regulations as the basis for their request for an FDA investigation and public hearing, including a regulation permitting an administrative hearing and a third-party citizens' petition when there is evidence of misconduct that could affect the public health (21 C.F.R. Sections 10.25, 10.30, 12, 13, 14, 15, or 16 and 54.2), and specifically, to look into any potential financial conflict of interests by 3M that could have influenced the outcome of its clinical trials (21 C.F.R. Section 54.4(1).)

In addition, in their letter to FDA the two Porton attorneys cited additional FDA regulatory authority: (1) to initiate an audit of data derived from the 3M investigators and its own internal (and still secret) technical report concerning 3M's fall 2007 BacLite clinical trials; and (2) to appoint an independent clinical investigator to re-conduct the 3M trial study because of the serious public health - potential life-death ramifications of 3M's clinical trial failure and errors pointed out by its own technical committee.

Authority for European / British Independent Public Health Investigations

The Porton attorneys also cited International Cooperation Agreements between the EU and its European Medicines Agency, the U.K.'s Healthcare Products Regulatory Agency (MHRA), and the FDA to allow the EU to request documents and to conduct its own investigation of 3M's BacLite clinical trial failures and the reasons they occurred, in contrast to the successful trials qualifying BacLite for sale within the EU.

"To this end, we intend to petition the EU European Medicines Agency and the U.K. MHRA to invoke their authority pursuant to International Agreements [and their own Good Clinical Practices Directives] to...undertake an investigation of 3M Corporation regarding its failed clinical trials," Davis and Hopper wrote in their letter to FDA.

In fact, the two Porton attorneys cited the U.K.'s Healthcare Regulatory Agency's requirements to conduct such an investigation when it is presented with "evidence that shows significant and unjustified departures...for the conduct of clinical trials, especially when such evidence shows the clinical data to be unreliable and/or there exists a number of non-compliances across areas of responsibility, indicating a systemic quality assurance failure" - "as is the case," Davis and Hopper wrote, "with 3M Corporation and the BacLite clinical trials."

FOR FURTHER INFORMATION: GO TO http://www.MRSA-INJUSTICE.com

(SEE FDA LETTER, ATTACHED FACTUAL CHRONOLOGY, RELEVANT DOCUMENTS, AND OTHER RELEVANT INFORMATION ON WEBSITE.)

    
    FOR FURTHER INQUIRIES CALL:
    U.S. MEDIA:
    Robert R. Hopper & Associates: +1-(763)-476-5809
    robertr.hopper@gmail.com

    Maddie Melendez: +1-(202)-756-8293
    mmelendez@lannyjdavis.com

    EUROPEAN MEDIA:
    Catherine Nicholls: +44-7789-644-979
    catherine@tetra-strategy.co.uk

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.